litlas
ログインアカウント作成

Philip J. Johnson

1978–2025 年に発表

別表記
Philip J Johnson
169
論文数
35,390
被引用数
106
h 指数
166
i10 指数

被引用数

Philip J. Johnson の年別被引用数1979 年: 被引用 1 件1980 年: 被引用 1 件1981 年: 被引用 1 件1982 年: 被引用 3 件1983 年: 被引用 3 件1984 年: 被引用 6 件1985 年: 被引用 10 件1986 年: 被引用 5 件1987 年: 被引用 9 件1988 年: 被引用 11 件1989 年: 被引用 8 件1990 年: 被引用 6 件1991 年: 被引用 13 件1992 年: 被引用 20 件1993 年: 被引用 20 件1994 年: 被引用 37 件1995 年: 被引用 33 件1996 年: 被引用 28 件1997 年: 被引用 32 件1998 年: 被引用 67 件1999 年: 被引用 78 件2000 年: 被引用 93 件2001 年: 被引用 143 件2002 年: 被引用 197 件2003 年: 被引用 151 件2004 年: 被引用 240 件2005 年: 被引用 207 件2006 年: 被引用 213 件2007 年: 被引用 197 件2008 年: 被引用 284 件2009 年: 被引用 179 件2010 年: 被引用 243 件2011 年: 被引用 203 件2012 年: 被引用 251 件2013 年: 被引用 182 件2014 年: 被引用 191 件2015 年: 被引用 229 件2016 年: 被引用 205 件2017 年: 被引用 212 件2018 年: 被引用 253 件2019 年: 被引用 948 件2020 年: 被引用 1,051 件2021 年: 被引用 1,085 件2022 年: 被引用 828 件2023 年: 被引用 674 件2024 年: 被引用 1,037 件2025 年: 被引用 373 件2026 年: 被引用 7 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,395 件、この内訳の 19.7%中国: 引用元論文 2,234 件、この内訳の 18.3%日本: 引用元論文 785 件、この内訳の 6.5%イギリス: 引用元論文 708 件、この内訳の 5.8%イタリア: 引用元論文 638 件、この内訳の 5.2%ドイツ: 引用元論文 543 件、この内訳の 4.5%香港: 引用元論文 450 件、この内訳の 3.7%フランス: 引用元論文 417 件、この内訳の 3.4%カナダ: 引用元論文 361 件、この内訳の 3%スペイン: 引用元論文 346 件、この内訳の 2.8%台湾: 引用元論文 318 件、この内訳の 2.6%韓国: 引用元論文 307 件、この内訳の 2.5%
0%19.7%その他 22%

機関

分野

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology15.8%
  • Neuroscience3.3%
  • Immunology and Microbiology1.4%
  • Engineering1%
  • Veterinary0.9%
  • その他3.7%

トピック

  • Hepatocellular Carcinoma Treatment and Prognosis12.9%
  • Liver Disease Diagnosis and Treatment7%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4.3%
  • Hepatitis B Virus Studies2.8%
  • Liver Disease and Transplantation2.3%
  • Hepatitis C virus research2.2%
  • その他68.5%

共著者

全論文

検索で開く
  1. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    著者: Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi, Shinji Satomura, Mabel Teng, Helen L. Reeves, James O’Beirne, Richard Fox, Anna Skowrońska, Daniel H. Palmer, Winnie Yeo, Frankie Mo, Paul B.S. Lai, Mercedes Iñarrairaegui, Stephen L. Chan, Bruno Sangro, Rebecca A. Miksad, Toshifumi Tada, Takashi Kumada, Hidenori Toyoda - Journal of Clinical Oncology 2014 被引用: 2,755

  2. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

    著者: Joong‐Won Park, Minshan Chen, M. Colombo, Lewis R. Roberts, Myron Schwartz, Pei‐Jer Chen, Masatoshi Kudo, Philip J. Johnson, Samuel Wagner, Lucinda Orsini, Morris Sherman - Liver International 2015 被引用: 1,256

  3. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

    著者: Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Kohichiroh Yasui, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Osamu Yokosuka, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai - Gut 2019 被引用: 723

  4. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

    著者: Philip J. Johnson, Qing Zhou, Doan Y Dao, Yuk Ming Dennis Lo - Nature Reviews Gastroenterology & Hepatology 2022 被引用: 318

  5. openalex_id:w4200584065

    著者: Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, Patrizia Carrieri, Geoffrey Dusheiko, Elisabetta Bugianesi, Rachel Pryke, Sharon Hutchinson, Bruno Sangro, Natasha K. Martin, Michele Cecchini, Mae Dirac, Annalisa Belloni, Miquel Serra‐Burriel, Cyriel Y. Ponsioen, Brittney S Sheena, Aliénor Lerouge, Marion Devaux, Nick Scott, Margaret Hellard, Henkjan J. Verkade, Ekkehard Sturm, Giulio Marchesini, Hannele Yki‐Järvinen, Christopher D. Byrne, Giovanni Targher, Aviad Tur‐Sinai, Damon Barrett, Michael Ninburg, Tatjana Reić, Alison Taylor, Tim Rhodes, Carla Treloar, Claus Petersen, Christoph Schramm, Robert Flisiak, Marieta Simonova, Albert Parés, Philip J. Johnson, Alessandro Cucchetti, Isabel Graupera, Christos Lionis, Elisa Pose, Núria Fabrellas, Ann T., Juan Manuel Mendive, Vincenzo Mazzaferro, Harry Rutter, Helena Cortez‐Pinto, Déirdre Kelly, Robyn Burton, Jeffrey V. Lazarus, Pere Ginès, Marı́a Buti, Philip N. Newsome, Patrizia Burra, Michael P. Manns 被引用: 245

  6. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

    著者: Rong Fan, George Papatheodoridis, Jian Sun, Hamish Innes, Hidenori Toyoda, Qing Xie, Shuyuan Mo, Vana Sypsa, Indra Neil Guha, Takashi Kumada, Junqi Niu, George Ν. Dalekos, Satoshi Yasuda, Eleanor Barnes, Jianqi Lian, Vithika Suri, Ramazan Idılman, Stephen T. Barclay, Xiaoguang Dou, Thomas Berg, Peter Hayes, John F. Flaherty, Yuanping Zhou, Zhengang Zhang, Marı́a Buti, Sharon Hutchinson, Yabing Guo, José Luís Calleja, Lanjia Lin, Longfeng Zhao, Yongpeng Chen, Harry L.A. Janssen, Chaonan Zhu, Lei Shi, Xiaoping Tang, Anuj Gaggar, Lai Wei, Jidong Jia, William L. Irving, Philip J. Johnson, Pietro Lampertico, Jinlin Hou - Journal of Hepatology 2020 被引用: 349

  7. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection

    著者: Anthony W.H. Chan, Jian‐Hong Zhong, Sarah Berhane, Hidenori Toyoda, Alessandro Cucchetti, Keqing Shi, Toshifumi Tada, Charing C. N. Chong, Bang‐De Xiang, Le‐Qun Li, Paul B.S. Lai, Vincenzo Mazzaferro, Marta García‐Fiñana, Masatoshi Kudo, Takashi Kumada, Sasan Roayaie, Philip J. Johnson - Journal of Hepatology 2018 被引用: 551

  8. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

    著者: Jan Best, Lars P. Bechmann, Jan‐Peter Sowa, Svenja Sydor, Alexander Dechêne, Kristina Pflanz, Sotiria Bedreli, Clemens Schotten, Andreas Geier, Thomas Berg, Janett Fischer, Arndt Vogel, Heike Bantel, Arndt Weinmann, Jörn M. Schattenberg, Yvonne Huber, Henning Wege, Johann von Felden, Kornelius Schulze, Dominik Bettinger, Robert Thimme, Friedrich Sinner, Kerstin Schütte, Karl Heinz Weiss, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Sarah Berhane, Marc Wichert, Dominik Heider, Guido Gerken, Philip J. Johnson, Ali Canbay - Clinical Gastroenterology and Hepatology 2019 被引用: 289

  9. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

    著者: Tim Meyer, Richard Fox, Yuk Ting, Paul J. Ross, Martin W. James, Richard Sturgess, Clive Stubbs, Deborah Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T.R. Jeffry Evans, Peter L. Collins, Richard Hubner, David Cunningham, John Primrose, Philip J. Johnson, Daniel H. Palmer - ˜The œLancet. Gastroenterology & hepatology 2017 被引用: 497

  10. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    著者: Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nóra Schweitzer, Arndt Vogel, Michael P. Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, JF Schlaak, Arndt Weinmann, Marcus A. Wörns, Peter R. Galle, Winnie Yeo, Frankie Mo, Stephen L. Chan, Helen L. Reeves, Trevor F. Cox, Philip J. Johnson - Clinical Gastroenterology and Hepatology 2016 被引用: 323

  11. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

    著者: Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai, on behalf of the TACTICS Study Group - Liver Cancer 2022 被引用: 128

  12. The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers

    著者: Philip J. Johnson, Sarah Pirrie, Trevor F. Cox, Sarah Berhane, Mabel Teng, Daniel H. Palmer, Janet Morse, Diana Hull, Gillian Patman, Chiaki Kagebayashi, Syed A. Hussain, Janine Graham, Helen L. Reeves, Shinji Satomura - Cancer Epidemiology Biomarkers & Prevention 2013 被引用: 335

  13. The ALBI score: From liver function in patients with HCC to a general measure of liver function

    著者: Hidenori Toyoda, Philip J. Johnson - JHEP Reports 2022 被引用: 194

  14. The role of hepatic resection in the treatment of hepatocellular cancer

    著者: Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong‐Won Park, Jijin Yang, Lünan Yan, Myron Schwartz, Guohong Han, Francesco Izzo, Mishan Chen, Jean‐Frédéric Blanc, Philip J. Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman - Hepatology 2015 被引用: 415

  15. Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma

    著者: Antonio Daniele Pinna, Tian Yang, Vincenzo Mazzaferro, Luciano De Carlis, Jian Zhou, Sasan Roayaie, Feng Shen, Carlo Sposito, Matteo Cescon, Stefano Di Sandro, Yifeng He, Philip J. Johnson, Alessandro Cucchetti - Annals of Surgery 2018 被引用: 219

  16. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

    著者: Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Kohei Akazawa, Kenichi Yoshimura, Philip J. Johnson, Yasuaki Arai, Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Kohei Akazawa, Kenichi Yoshimura, Philip Johnson, Yasuaki Arai - ˜The œLancet. Gastroenterology & hepatology 2018 被引用: 309

  17. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer

    著者: Latha Kadalayil, Roberto Benini, Lalit Pallan, James O’Beirne, Laura Marelli, Dominic Yu, Allan Hackshaw, Richard Fox, Philip J. Johnson, Andrew K. Burroughs, Daniel H. Palmer, Tim Meyer - Annals of Oncology 2013 被引用: 378

  18. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach

    著者: Guohong Han, Sarah Berhane, Hidenori Toyoda, Dominik Bettinger, Omar Elshaarawy, Anthony W.H. Chan, Martha M. Kirstein, Cristina Mosconi, Florian Hucke, Daniel H. Palmer, David J. Pinato, Rohini Sharma, Diego Ottaviani, Jeong Won Jang, Tim A. Labeur, Otto M. van Delden, Mario Pirisi, Nick Stern, Bruno Sangro, Tim Meyer, Waleed Fateen, Marta García‐Fiñana, Asmaa Gomaa, Imam Waked, Eman Rewisha, Guruprasad P. Aithal, Simon Travis, Masatoshi Kudo, Alessandro Cucchetti, Markus Peck‐Radosavljevic, R. Bart Takkenberg, Stephen L. Chan, Arndt Vogel, Philip J. Johnson - Hepatology 2019 被引用: 130

  19. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    著者: Philip J. Johnson, Shukui Qin, Joong‐Won Park, Ronnie T.P. Poon, Jean‐Luc Raoul, Philip A. Philip, Chih‐Hung Hsu, Tsung‐Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee Chao, Éveline Boucher, Kwang‐Hyub Han, Seung Woon Paik, Jorge Alberto Robles-Aviña, Masatoshi Kudo, Lünan Yan, Abhasnee Sobhonslidsuk, Д. В. Комов, Thomas Decaens, Won Young Tak, Long‐Bin Jeng, David Liu, Rana Ezzeddine, Ian Walters, Ann‐Lii Cheng - Journal of Clinical Oncology 2013 被引用: 775

  20. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis

    著者: Julien Edeline, Ángela Lamarca, Mairéad G. McNamara, Timothy W. Jacobs, Richard Hubner, Dan Palmer, Bas Groot Koerkamp, Philip J. Johnson, Boris Guiu, Juan W. Valle - Cancer Treatment Reviews 2021 被引用: 108

  21. Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis

    著者: Yuk Ming Dennis Lo, Mark Tein, Tze Kin Lau, Christopher J. Haines, Tse Ngong Leung, Priscilla M.K. Poon, James S. Wainscoat, Philip J. Johnson, Allan M.Z. Chang, N M Hjelm - The American Journal of Human Genetics 1998 被引用: 1,658

  22. Limited regeneration in long acellular nerve allografts is associated with increased Schwann cell senescence

    著者: Maryam Saheb-Al-Zamani, Yan Yan, Scott J. Farber, Daniel A. Hunter, Piyaraj Newton, Matthew D. Wood, Sheila A. Stewart, Philip J. Johnson, Susan E. Mackinnon - Experimental Neurology 2013 被引用: 215

  23. Regenerative Peripheral Nerve Interface Viability and Signal Transduction with an Implanted Electrode

    著者: Theodore A. Kung, Nicholas B. Langhals, David C. Martin, Philip J. Johnson, Paul S. Cederna, Melanie G. Urbanchek - Plastic & Reconstructive Surgery 2014 被引用: 177

  24. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma

    著者: Winnie Yeo, Tony Mok, Benny Zee, Thomas W. T. Leung, Paul B.S. Lai, Wan Yee Lau, Jane Koh, Frankie Mo, Simon C.H. Yu, Anthony T.�C. Chan, Pun Hui, Brigette Ma, Kwok Chi Lam, Wing Ming Ho, Herman Wong, Amanda M. Y. Tang, Philip J. Johnson - JNCI Journal of the National Cancer Institute 2005 被引用: 589